Dark

Check out our Level2View

ABIO
ARCA biopharma, Inc.
stock NASDAQ

Inactive

Aug 30, 2024

28.80USD-4.000%(-1.20)24,238

Pre-market

0.00USD-100.000%(-30.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

08:30AM EST -- Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF) -- In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for GencaroTM compared to metoprolol GlobeNewswire Inc

Dec 2, 2021

12:07PM EST ARCA Biopharma Expects Data Readout From Mid-Stage COVID-19 Trial In Q1 2022 Benzinga

08:34AM EST UPDATE: ARCA bio Sees Topline Readout Of Trial Results From rNAPc2 In Q1'22 Benzinga

08:34AM EST ARCA biopharma Reports Completed Enrollment In Phase 2b ASPEN-COVID-19 Trial Evaluating rNAPc2 As Potential Treatment For Patients Hospitalized With COVID-19 Benzinga

08:30AM EST -- Topline readout of clinical trial results anticipated in first quarter of 2022 GlobeNewswire Inc

Nov 2, 2021

05:24PM EDT ARCA biopharma Q3 EPS $(0.33), Same YoY Benzinga

Oct 29, 2021

09:00AM EDT ARCA Biopharma Rises 11% As Interim Review Greenlights RTTNews

08:00AM EDT The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs Benzinga

06:14AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT). RTTNews

05:13AM EDT ARCA Biopharma Shares Rise 22% Premarket; Co Announced on Thursday ASPEN-COVID-19 Data And Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial To Completion Based On Interim Analysis Of Efficacy And Safety Data Benzinga

Oct 28, 2021

05:18PM EDT ARCA Biopharma Announces ASPEN-COVID-19 Data And Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial To Completion Based On Interim Analysis Of Efficacy And Safety Data Benzinga

Sep 16, 2021

08:36AM EDT ARCA Biopharma Announces Enrollment Of First International Patient In Phase 2b Clinical Trial Evaluating rNAPc2 As Potential Treatment For COVID-19 Benzinga

08:30AM EDT -- First international patient enrolled in Brazil -- Trial approximately 75% enrolled -- rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients -- Topline trial data anticipated in the fourth quarter of 2021 GlobeNewswire Inc

Aug 16, 2021

08:05AM EDT ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Jeff Dekker, Chief Financial Officer, will present at the Q3 Virtual Investor Summit being held August 17-18, 2021. GlobeNewswire Inc

Aug 9, 2021

08:02AM EDT ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 Benzinga

08:00AM EDT ARCA biopharma Announces Submission of PCT Patent Application for GlobeNewswire Inc

Aug 4, 2021

05:22PM EDT ARCA biopharma Q2 EPS $(0.34) Up From $(0.73) YoY Benzinga

Jul 29, 2021

01:45PM EDT ARCA Biopharma Early Wednesday Said Gencaro Atrial Fibrillation Phase 2B Results Selected For Publication Benzinga

Jul 28, 2021

08:00AM EDT Gencaro Atrial Fibrillation Phase 2B Results Selected for GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 13, 2021

08:05AM EDT ARCA biopharma Says Received Approval In Argentina And Brazil To Enroll Patients In ASPEN-COVID-19 Benzinga

08:02AM EDT -- rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients -- Trial expanded to South America, with regulatory approvals for Argentina and Brazil -- Target trial enrollment increased to 160 patients -- Topline trial data anticipated in the fourth quarter of 2021 GlobeNewswire Inc

Jul 9, 2021

08:03AM EDT ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Thomas Keuer, Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021. GlobeNewswire Inc

Jul 7, 2021

08:28AM EDT ARCA biopharma Inc. (ABIO) said that it has reached a patent assignment agreement with the University Medical Center of Johannes Gutenberg University Mainz, Germany that will provide exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications. RTTNews

08:08AM EDT ARCA Gets Exclusive World-wide Patent Rights To Use Of RNAPc2 As Potential Treatment For COVID-19 RTTNews

08:00AM EDT ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement Benzinga

08:00AM EDT -- Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

04:41PM EDT ARCA biopharma Q1 EPS $(0.33) Up From $(0.83) YoY Benzinga

04:15PM EDT -- Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 GlobeNewswire Inc

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 5, 2021

04:05PM EDT ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development. GlobeNewswire Inc

May 3, 2021

04:53PM EDT ARCA biopharma Announces C. Jeff Dekker To Be Appointed Chief Financial Officer Benzinga

04:30PM EDT ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced C. Jeff Dekker as its Chief Financial Officer, effective May 10, 2021, following Brian Selbys planned departure after 14 years of service with the Company. GlobeNewswire Inc

Mar 22, 2021

05:10PM EDT ARCA biopharma S-3 Shows Registration For $150M Mixed Securities Shelf Offering Benzinga

Mar 19, 2021

10:44AM EDT ARCA Biopharma shares were trading higher after the company reported FY20 EPS results up from last year. Benzinga

Mar 18, 2021

04:31PM EDT ARCA biopharma FY20 EPS $(2.07) vs $(4.15) In FY19 Benzinga

04:30PM EDT -- Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 GlobeNewswire Inc

Dec 15, 2020

08:34AM EST ARCA biopharma Announces First Patients Enrolled In ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 As A Potential Treatment For COVID-19 Benzinga

08:30AM EST ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 GlobeNewswire Inc

Dec 9, 2020

05:40PM EST ARCA biopharma Announces Location Change for 2020 Annual Meeting GlobeNewswire Inc

Nov 23, 2020

08:30AM EST -- Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not -- AB201 is the only novel compound being developed for COVID Associated Coagulopathy -- Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December -- Topline trial data anticipated Q2 2021 GlobeNewswire Inc

Nov 2, 2020

08:33AM EST ARCA Biopharma Sees Phase 2b Trial For AB201 Starting In Q4 Benzinga

08:31AM EST ARCA biopharma Q3 EPS $(0.33) Up From $(0.76) YoY Benzinga

08:30AM EST -- Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarter -- Topline data from trial anticipated Q2 2021 GlobeNewswire Inc

Oct 7, 2020

08:30AM EDT ARCA biopharma Reports FDA Approval Of Investigational New Drug Application For AB201 As Potential Treatment For COVID-19 Benzinga

08:30AM EDT -- Initiation of Phase 2b clinical trial anticipated in Q4 2020 -- Trial to enroll approximately 100 patients hospitalized with COVID-19 -- Topline data anticipated Q2 2021 GlobeNewswire Inc

Oct 5, 2020

04:30PM EDT ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the promotion of Debra Marshall, MD, FACC to Chief Medical Officer, and Sharon Perry, RAC, to Vice President, Regulatory Affairs and Quality. GlobeNewswire Inc

Sep 21, 2020

08:33AM EDT ARCA biopharma Inc. (ABIO) said Monday that it has submitted an Investigational New Drug or IND application with the U.S. Food and Drug Administration or FDA under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 for the treatment of patients hospitalized with COVID-19. RTTNews

08:18AM EDT ARCA Biopharma Submits IND Application With FDA Under CTAP To Evaluate AB201 RTTNews

08:01AM EDT ARCA biopharma Announces Submission Of IND Application To US FDA For AB201 As A Potential Treatment For COVID-19 Benzinga

08:00AM EDT ARCA biopharma Announces Submission of IND Application to U.S. FDA GlobeNewswire Inc

Aug 12, 2020

08:15AM EDT ARCA Biopharma Announces Completion Of FDA Pre-IND Consultation Under Coronavirus TreatmentAcceleration Program For AB201 As Potential Treatment For Severe COVID-19 Benzinga

Aug 5, 2020

05:10PM EDT ARCA biopharma Q2 EPS $(0.73) Up From $(1.14) YoY Benzinga

Share